Person:
GEBİTEKİN, CENGİZ

Profile Picture

Email Address

Birth Date

Research Projects

Organizational Units

OrgUnit Logo
Organizational Unit

Job Title

Last Name

GEBİTEKİN

First Name

CENGİZ

Name

Filters

2020 - 20213
Reset filters

Settings

Search Results

Now showing 1 - 3 of 3
  • Thumbnail Image
    Publication
    Comparison of survival results of patients with t0 and t1-2-3 in pathological t staging in patients with non-small cell lung cancer who underwent surgery after neoadjuvant treatment
    (Termedia Publishing House, 2020-01-01) Kermenli, Tayfun; Melek, Hüseyin; Bayram, Ahmet Sami; Gebitekin, Cengiz; MELEK, HÜSEYİN; BAYRAM, AHMET SAMİ; GEBİTEKİN, CENGİZ; Bursa Uludağ Üniversitesi/Tıp Fakültesi.; 0000-0003-0684-0900; 0000-0003-1822-8153; AAE-1069-2022; AAI-5039-2021; JCE-0097-2023; ABB-7580-2020
    Aim: In this study, we aimed to compare the survival results of patients who underwent neoadjuvant treatment with NSCLC between March 1997 and August 2014 and were found to have T0N0 and T1-2-3/N0.Material and methods: A hundred ninety-five patients who had complete neoadjuvant therapy, complete lung resection and lymph node dissection, and pathologically diagnosed as T0 or T1-2-3/N0, M0 were included in the study.Results: Of the 195 patients included in the study, 181 were male, 14 were female and the mean age of the patients was 57.9. The mean age of the groups was as follows: group 1: 58.1, group 2: 57.7, group 3: 59.7 and group 4: 56.8. In our series the most common complication was atelectasis (n = 19). Others were prolonged air leak (n = 16), pneumonia (n = 12), apical pleural space (n = 6), wound infection (n = 3), cardiac problems (n = 3), hematoma (n = 3), bronchopleural fistula (n = 3), empyema (n = 2), chylothorax (n = 1). The 5-year survival rate for patients in the T0N0 group was 76.3%. This rate was 71.8% in group 2, 63.6% in group 3 and 44.1% in group 4.Conclusions: Survival was found to be better in patients who underwent surgery after neoadjuvant therapy and had a complete pathological response. We believe that we can provide better results with the increase in the number of cases detected as TxN0 after the neoadjuvant treatment and prolongation of the follow-up period.
  • Thumbnail Image
    Publication
    Radiotherapy in patients with trachea tumours: A retrospective study and literature review
    (Kare Yayınevi, 2020-01-01) Sarihan, Süreyya; Bayram, Ahmet Sami; Melek, Hüseyin; Gebitekin, Cengiz; SARIHAN, SÜREYYA; BAYRAM, AHMET SAMİ; MELEK, HÜSEYİN; GEBİTEKİN, CENGİZ; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Radyasyon Onkolojisi Anabilim Dalı.; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Göğüs Cerrahisi Anabilim Dalı.; 0000-0003-4816-5798; 0000-0003-0684-0900; AAE-1069-2022; AAI-5039-2021; JCE-0097-2023; ABB-7580-2020; AAH-4970-2021
    OBJECTIVEIn this study, we aimed to evaluate our patients with tracheal tumours treated with primary or adjuvant radiotherapy (RT) and to review the current literature on the subject.METHODSBetween 1998 and 2017, eight patients underwent RT. Their median age was 37 years (15-53). The diagnosis was adenoid cystic carcinoma in five patients, squamous cell carcinoma in three patients and mucoepidermoid carcinoma in one patient. Resection type was R0 (1), R1 (4), R2 (1), and biopsy (2). The median tumour size was 2.6 cm (2-5). Median 59.4 Gy RT (32.4-66.6) was given, and weekly cisplatin was administered to four patients concomitantly.RESULTSWith a median follow-up of 85 months (4-189), five patients were alive. The 5-year overall and disease-free survival rates were 83% and 67%, respectively. There was no local recurrence in any patient. In one patient who had a complete response with curative chemo-RT, dilatation was performed five times in 10 years because tracheal stenosis developed at 60 months.CONCLUSIONTrachea tumours are rare, and the primary treatment is surgery. Adjuvant RT is controversial in R0 cases. In unresectable cases, RT is the primary treatment modality. We believe that our treatment results will contribute to the literature on the subject.
  • Thumbnail Image
    Publication
    Intercostal nerve reconstruction for severe compensatory hyperhidrosis: The gebitekin technique
    (Elsevier, 2021-05-20) Gebitekin, Cengiz; Melek, Hüseyin; Çetinkaya, Gamze; Özer, Erhan; Yentürk, Eylem; Sevinç, Tolga Evrim; Bayram, Ahmet Sami; GEBİTEKİN, CENGİZ; MELEK, HÜSEYİN; Çetinkaya, Gamze; ÖZER, ERHAN; YENTÜRK, EYLEM; SEVİNÇ, TOLGA EVRİM; BAYRAM, AHMET SAMİ; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Göğüs Cerrahisi Anabilim Dalı; 0000-0003-0684-0900; 0000-0003-1822-8153; 0000-0002-4848-1566; JCE-0097-2023; ABB-7580-2020; JDW-2654-2023; AAE-1069-2022; AAI-5039-2021; FNZ-9525-2022; JRB-0865-2023; IGQ-1108-2023
    Compensatory sweating (CS) is the most common and disabling complication of endoscopic thoracic sympathectomy and represents an unmet clinical challenge. Our surgical hypothesis is to generate a parallel pathway to the damaged part of the sympathetic nerve, similar to the Kuntz nerve, by reconstructing the 2 healthy intercostal nerves, thus treating CS. Here, we present a novel videothoracoscopic technique involving bilateral intercostal nerve reconstruction in patients with severe CS after endoscopic thoracic sympathectomy.(Ann Thorac Surg 2021;111:e443-6)(c) 2021 by The Society of Thoracic Surgeons